** Heart disease drugmaker Cytokinetics' shares CYTK.O rise 5.7% to $40.17
** Rival Bristol Myers Squibb BMY.N stressed that it expects steady growth of heart drug Camzyos in 2025
** Says it is observing "strong global demand, high persistency and new patients coming on to therapy each week," especially after a recent update to its prescribing information
** The update allows for less frequent monitoring and simplifies treatment process for patients and doctors, J.P. Morgan analysts say
** "We also think the label update bodes well for the overall class and could expand the hypertrophic cardiomyopathy $(HCM)$ market," — brokerage
** CYTK is developing a rival heart drug, aficamten, to treat non-obstructive form of HCM, an inherited condition characterized by thickening of heart muscles
** CYTK is expected to report Q1 results on May 6
** As of last close, CYTK has fallen 14.7% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。